Browse
Submit Data
Databases
API
Help

Dataset Information

12 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

AplusB: A Web Application for Investigating A + B Designs for Phase I Cancer Clinical Trials.

ABSTRACT: In phase I cancer clinical trials, the maximum tolerated dose of a new drug is often found by a dose-escalation method known as the A + B design. We have developed an interactive web application, AplusB, which computes and returns exact operating characteristics of A + B trial designs. The application has a graphical user interface (GUI), requires no programming knowledge and is free to access and use on any device that can open an internet browser. A customised report is available for download for each design that contains tabulated operating characteristics and informative plots, which can then be compared with other dose-escalation methods. We present a step-by-step guide on how to use this application and provide several illustrative examples of its capabilities.

SUBMITTER: Wheeler GM

PROVIDER: S-EPMC4942070 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

AplusB: A Web Application for Investigating A + B Designs for Phase I Cancer Clinical Trials.

Wheeler Graham M GM Sweeting Michael J MJ Mander Adrian P AP

PloS one 20160712 7

In phase I cancer clinical trials, the maximum tolerated dose of a new drug is often found by a dose-escalation method known as the A + B design. We have developed an interactive web application, AplusB, which computes and returns exact operating characteristics of A + B trial designs. The application has a graphical user interface (GUI), requires no programming knowledge and is free to access and use on any device that can open an internet browser. A customised report is available for download ...[more]

PMID: 27403961

Similar Datasets

Optimal sequential enrichment designs for phase II clinical trials.

Project description:In the early phase development of molecularly targeted agents (MTAs), a commonly encountered situation is that the MTA is expected to be more effective for a certain biomarker subgroup, say marker-positive patients, but there is no adequate evidence to show that the MTA does not work for the other subgroup, that is, marker-negative patients. After establishing that marker-positive patients benefit from the treatment, it is often of great clinical interest to determine whether the treatment benefit extends to marker-negative patients. The authors propose optimal sequential enrichment (OSE) designs to address this practical issue in the context of phase II clinical trials. The OSE designs evaluate the treatment effect first in marker-positive patients and then in marker-negative patients if needed. The designs are optimal in the sense that they minimize the expected sample size or the maximum sample size under the null hypothesis that the MTA is futile. An efficient, accurate optimization algorithm is proposed to find the optimal design parameters. One important advantage of the OSE design is that the go/no-go interim decision rules are specified prior to the trial conduct, which makes the design particularly easy to use in practice. A simulation study shows that the OSE designs perform well and are ethically more desirable than the commonly used marker-stratified design. The OSE design is applied to an endometrial carcinoma trial. Copyright © 2016 John Wiley & Sons, Ltd.

| S-EPMC5138118 | biostudies-literature

Adaptive Designs for Clinical Trials: Application to Healthcare Epidemiology Research.

Project description:Clinical trials with adaptive designs use data that accumulate during the course of the study to modify study elements in a prespecified manner. The goal is to provide flexibility such that a trial can serve as a definitive test of its primary hypothesis, preferably in a shorter time period, involving fewer human subjects, and at lower cost. Elements that may be modified include the sample size, end points, eligible population, randomization ratio, and interventions. Accumulating data used to drive these modifications include the outcomes, subject enrollment (including factors associated with the outcomes), and information about the application of the interventions. This review discusses the types of adaptive designs for clinical trials, emphasizing their advantages and limitations in comparison with conventional designs, and opportunities for applying these designs to healthcare epidemiology research, including studies of interventions to prevent healthcare-associated infections, combat antimicrobial resistance, and improve antimicrobial stewardship.

| S-EPMC6018921 | biostudies-literature

Interactive calculator for operating characteristics of phase I cancer clinical trials using standard 3+3 designs.

Project description:Among various Phase I clinical trial designs, rule-based standard 3 + 3 designs are the most widely utilized for their simplicity and robustness. It is necessary to define crucial operating characteristics of a Phase I clinical trial before it starts. Based on the assumed probability of dose limiting toxicity (DLT) at each tested dose level, Lin and Shih elaborated formulas to calculate the five key operating characteristics of Phase I clinical trials using the two subtypes of standard 3 + 3 designs (with vs without dose de-escalation): probability of each dose level being chosen as the maximum tolerated dose (MTD); expected number of patients treated at each dose level; expected number of patients experiencing DLT at each dose level; target toxicity level (TTL) (expected probability of DLT at MTD); expected total number of patients experiencing DLT. Understanding these formulas requires advanced statistical knowledge and the formulas are too complicated to be used directly. To facilitate their application, we have developed stand-alone interactive software for convenient calculation of these key operating characteristics. The calculated results are presented in tables and plots that can be saved and easily edited for further use. Some examples of calculation using the software are presented and discussed.

| S-EPMC6261803 | biostudies-other

Optimal adaptive two-stage designs for early phase II clinical trials.

Project description:Simon's optimal two-stage design has been widely used in early phase clinical trials for Oncology and AIDS studies with binary endpoints. With this approach, the second-stage sample size is fixed when the trial passes the first stage with sufficient activity. Adaptive designs, such as those due to Banerjee and Tsiatis (2006) and Englert and Kieser (2013), are flexible in the sense that the second-stage sample size depends on the response from the first stage, and these designs are often seen to reduce the expected sample size under the null hypothesis as compared with Simon's approach. An unappealing trait of the existing designs is that they are not associated with a second-stage sample size, which is a non-increasing function of the first-stage response rate. In this paper, an efficient intelligent process, the branch-and-bound algorithm, is used in extensively searching for the optimal adaptive design with the smallest expected sample size under the null, while the type I and II error rates are maintained and the aforementioned monotonicity characteristic is respected. The proposed optimal design is observed to have smaller expected sample sizes compared to Simon's optimal design, and the maximum total sample size of the proposed adaptive design is very close to that from Simon's method. The proposed optimal adaptive two-stage design is recommended for use in practice to improve the flexibility and efficiency of early phase therapeutic development.

| S-EPMC4777673 | biostudies-literature

Model-Assisted Designs for Early-Phase Clinical Trials: Simplicity Meets Superiority.

Project description:Drug development enterprise is struggling because of prohibitively high costs and slow progress. There is urgent need for adoption of novel adaptive designs to improve the efficiency and success of clinical trials. A major barrier is that many conventional designs are inadequate for modern drug development, yet most novel adaptive designs are difficult to understand, require complicated statistical modeling, demand complex computation, and need expensive infrastructure for implementation. The objective of this article is to introduce and review a class of novel adaptive designs, known as model-assisted designs, to remove this barrier and increase the use of novel adaptive designs. Model-assisted designs enjoy superior performance comparable to more complicated, model-based adaptive designs, but their decision rule can be pretabulated and included in the protocol-thus implemented as simply as the conventional designs. We review state-of-the-art model-assisted designs for phase I clinical trials for single-agent, drug-combination and late-onset toxicity scenarios. We also briefly introduce model-assisted designs for phase II trials to handle binary, coprimary endpoints and delayed response. Freely available user-friendly software and trial examples (trialdesign.org) facilitate the adoption of model-assisted designs.

| S-EPMC7446379 | biostudies-literature

Bayesian designs to account for patient heterogeneity in phase II clinical trials.

Project description:Between-patient heterogeneity is very common in clinical trials. This complicates treatment evaluation, due to known prognostic subgroup effects or potential treatment-subgroup interactions. We review two Bayesian phase II clinical trial designs that account explicitly for patient heterogeneity. The first design uses analysis of covariance to assess treatment effects in subgroups known to have different prognoses. The second design uses a hierarchical model for settings where, a priori, the experimental treatment effects in the subgroups are assumed to be exchangeable.Compared with simpler designs that ignore patient heterogeneity, each design provides substantial improvements by reducing both false positive and false negative rates and focusing resources on subgroups where an experimental treatment is more likely to provide an advance over standard therapy. In either case, accounting for potential treatment-subgroup interactions is extremely important.Due to the rapidly increasing number of potential new treatments to be evaluated clinically, increasing costs and limited resources, it is critically important to perform early phase clinical trials efficiently. The new Bayesian methods described here and other related methods provide efficient, broadly applicable tools to address these problems.

| S-EPMC5555403 | biostudies-other

Modified Simon's minimax and optimal two-stage designs for single-arm phase II cancer clinical trials.

Project description:Simon's two-stage design and the admissible two-stage design have been commonly used in practice for single-arm phase II clinical trials when the primary endpoint is binary. The ethical benefit of the two-stage design over the single-stage design is attained by the early termination of the trial when the treatment seems to be inactive. While Simon's optimal design is the two-stage design that minimizes the expected number of subjects under the null hypothesis, the probability of falsely declaring futility after the first stage frequently seems undesirably high. In Simon's minimax design, however, it is often the case that a high proportion of the total planned subjects are evaluated in the first stage, and thus the ethical benefit may not be achieved. In this paper, we propose modified minimax and optimal two-stage designs which guarantee not only type I and II error rates but also reasonable sample size proportions in the first stage, while maintaining the probability of falsely declaring futility under a pre-selected level. The characteristics of the modified two-stage design will be compared with those of Simon's and the admissible two-stage design. The modified minimax design yields a design that requires modest increase in 29% of cases, while the modified optimal design saves 1 to 13 subjects in 81% of cases for β = 0.2. The modified design approach provides investigators with an alternative when the sample sizes of Simon's designs are severely unbalanced or the Type II error is unacceptably high after the first stage.

| S-EPMC6611508 | biostudies-literature

A web application for the design of multi-arm clinical trials.

Project description:BACKGROUND:Multi-arm designs provide an effective means of evaluating several treatments within the same clinical trial. Given the large number of treatments now available for testing in many disease areas, it has been argued that their utilisation should increase. However, for any given clinical trial there are numerous possible multi-arm designs that could be used, and choosing between them can be a difficult task. This task is complicated further by a lack of available easy-to-use software for designing multi-arm trials. RESULTS:To aid the wider implementation of multi-arm clinical trial designs, we have developed a web application for sample size calculation when using a variety of popular multiple comparison corrections. Furthermore, the application supports sample size calculation to control several varieties of power, as well as the determination of optimised arm-wise allocation ratios. It is built using the Shiny package in the R programming language, is free to access on any device with an internet browser, and requires no programming knowledge to use. It incorporates a variety of features to make it easier to use, including help boxes and warning messages. Using design parameters motivated by a recently completed phase II oncology trial, we demonstrate that the application can effectively determine and evaluate complex multi-arm trial designs. CONCLUSIONS:The application provides the core information required by statisticians and clinicians to review the operating characteristics of a chosen multi-arm clinical trial design. The range of designs supported by the application is broader than other currently available software solutions. Its primary limitation, particularly from a regulatory agency point of view, is its lack of validation. However, we present an approach to efficiently confirming its results via simulation.

| S-EPMC6995188 | biostudies-literature

Extended two-stage adaptive designs with three target responses for phase II clinical trials.

Project description:We develop a nature-inspired stochastic population-based algorithm and call it discrete particle swarm optimization to find extended two-stage adaptive optimal designs that allow three target response rates for the drug in a phase II trial. Our proposed designs include the celebrated Simon's two-stage design and its extension that allows two target response rates to be specified for the drug. We show that discrete particle swarm optimization not only frequently outperforms greedy algorithms, which are currently used to find such designs when there are only a few parameters; it is also capable of solving design problems posed here with more parameters that greedy algorithms cannot solve. In stage 1 of our proposed designs, futility is quickly assessed and if there are sufficient responders to move to stage 2, one tests one of the three target response rates of the drug, subject to various user-specified testing error rates. Our designs are therefore more flexible and interestingly, do not necessarily require larger expected sample size requirements than two-stage adaptive designs. Using a real adaptive trial for melanoma patients, we show our proposed design requires one half fewer subjects than the implemented design in the study.

| S-EPMC5515697 | biostudies-literature

HIVToolbox, an integrated web application for investigating HIV.

Project description:Many bioinformatic databases and applications focus on a limited domain of knowledge federating links to information in other databases. This segregated data structure likely limits our ability to investigate and understand complex biological systems. To facilitate research, therefore, we have built HIVToolbox, which integrates much of the knowledge about HIV proteins and allows virologists and structural biologists to access sequence, structure, and functional relationships in an intuitive web application. HIV-1 integrase protein was used as a case study to show the utility of this application. We show how data integration facilitates identification of new questions and hypotheses much more rapid and convenient than current approaches using isolated repositories. Several new hypotheses for integrase were created as an example, and we experimentally confirmed a predicted CK2 phosphorylation site. Weblink: [http://hivtoolbox.bio-toolkit.com].

| S-EPMC3102074 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data